Compare Panacea Biotech with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs SUN PHARMA - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH SUN PHARMA PANACEA BIOTECH/
SUN PHARMA
 
P/E (TTM) x 10.5 22.3 47.1% View Chart
P/BV x 2.2 2.6 85.1% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 PANACEA BIOTECH   SUN PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-19
SUN PHARMA
Mar-19
PANACEA BIOTECH/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs354679 52.1%   
Low Rs138375 36.8%   
Sales per share (Unadj.) Rs74.6121.1 61.5%  
Earnings per share (Unadj.) Rs6.713.4 49.9%  
Cash flow per share (Unadj.) Rs15.520.7 74.9%  
Dividends per share (Unadj.) Rs02.75 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs57.2172.6 33.1%  
Shares outstanding (eoy) m61.252,399.26 2.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.34.4 75.8%   
Avg P/E ratio x36.839.4 93.4%  
P/CF ratio (eoy) x15.925.5 62.3%  
Price / Book Value ratio x4.33.1 140.7%  
Dividend payout %020.6 0.0%   
Avg Mkt Cap Rs m15,0611,264,650 1.2%   
No. of employees `0002.317.5 13.2%   
Total wages/salary Rs m1,47159,671 2.5%   
Avg. sales/employee Rs Th1,973.616,608.1 11.9%   
Avg. wages/employee Rs Th635.63,409.6 18.6%   
Avg. net profit/employee Rs Th176.81,833.8 9.6%   
INCOME DATA
Net Sales Rs m4,567290,659 1.6%  
Other income Rs m4510,255 0.4%   
Total revenues Rs m4,612300,914 1.5%   
Gross profit Rs m2,03063,076 3.2%  
Depreciation Rs m54017,533 3.1%   
Interest Rs m1,0485,553 18.9%   
Profit before tax Rs m48650,246 1.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m776,009 1.3%   
Profit after tax Rs m40932,093 1.3%  
Gross profit margin %44.421.7 204.8%  
Effective tax rate %15.912.0 132.6%   
Net profit margin %9.011.0 81.1%  
BALANCE SHEET DATA
Current assets Rs m2,415310,692 0.8%   
Current liabilities Rs m9,077173,396 5.2%   
Net working cap to sales %-145.947.2 -308.9%  
Current ratio x0.31.8 14.8%  
Inventory Days Days6599 65.7%  
Debtors Days Days71112 63.6%  
Net fixed assets Rs m8,333232,477 3.6%   
Share capital Rs m612,399 2.6%   
"Free" reserves Rs m3,443411,691 0.8%   
Net worth Rs m3,504414,091 0.8%   
Long term debt Rs m46115,226 3.0%   
Total assets Rs m13,755646,938 2.1%  
Interest coverage x1.510.0 14.6%   
Debt to equity ratio x0.10 358.0%  
Sales to assets ratio x0.30.4 73.9%   
Return on assets %10.65.8 182.1%  
Return on equity %11.77.8 150.6%  
Return on capital %38.710.2 380.6%  
Exports to sales %20.90-   
Imports to sales %8.10-   
Exports (fob) Rs m954NA-   
Imports (cif) Rs m372NA-   
Fx inflow Rs m1,20366,025 1.8%   
Fx outflow Rs m46738,610 1.2%   
Net fx Rs m73627,415 2.7%   
CASH FLOW
From Operations Rs m1,04921,965 4.8%  
From Investments Rs m-54-6,813 0.8%  
From Financial Activity Rs m-1,011-27,305 3.7%  
Net Cashflow Rs m-20-8,442 0.2%  

Share Holding

Indian Promoters % 74.5 63.7 117.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 5.1 11.7%  
FIIs % 1.3 23.0 5.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 8.3 284.3%  
Shareholders   10,259 133,026 7.7%  
Pledged promoter(s) holding % 35.1 0.5 6,617.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   SHASUN PHARMA  DR. REDDYS LAB  GSK PHARMA  FULFORD INDIA  WYETH LTD  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 181 Points Higher; Energy and Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours but ended their session off day's high.

Related Views on News

STRIDES PHARMA SCIENCE Surges by 5%; BSE HEALTHCARE Index Up 2.5% (Market Updates)

Nov 20, 2019 | Updated on Nov 20, 2019

STRIDES PHARMA SCIENCE share price has surged by 5% and its current market price is Rs 403. The BSE HEALTHCARE is up by 2.5%. The top gainers in the BSE HEALTHCARE Index are STRIDES PHARMA SCIENCE (up 5.4%) and SUN PHARMA (up 6.9%). The top losers are TORRENT PHARMA (down 0.1%) and PROCTER & GAMBLE HEALTH (down 0.2%).

SUN PHARMA Surges by 7%; BSE HEALTHCARE Index Up 2.4% (Market Updates)

Nov 20, 2019 | Updated on Nov 20, 2019

SUN PHARMA share price has surged by 7% and its current market price is Rs 461. The BSE HEALTHCARE is up by 2.4%. The top gainers in the BSE HEALTHCARE Index are SUN PHARMA (up 6.9%) and STRIDES PHARMA SCIENCE (up 5.2%). The top losers are PROCTER & GAMBLE HEALTH (down 0.2%) and ERIS LIFESCIENCES LIMITED (down 0.2%).

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Nov 20, 2019 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - J.B.CHEMICALS COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS